Susan O'Brien

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Neoplasm Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
O'Brien Susan; Moore Joseph O; Boyd Thomas E; Larratt Loree M; Skotnicki Aleksander B; Koziner Benjamin; Chanan-Khan Asher A; Seymour John F; Gribben John; Itri Loretta M; Rai Kanti R
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Bueso-Ramos Carlos; Abruzzo Lynne; Pierce Sherry; Shan Jianqin; Issa Jean-Pierre; Garcia-Manero Guillermo
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Susan O'Brien (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ravandi Farhad; Aribi Ahmed; O'Brien Susan; Faderl Stefan; Jones Dan; Ferrajoli Alessandra; Huang Xuelin; York Sergernne; Pierce Sherry; Wierda William; Kontoyiannis Dimitrios; Verstovsek Srdan; Pro Barbara; Fayad Luis; Keating Michael; Kantarjian Hagop
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: O'Brien Susan; Moore Joseph O; Boyd Thomas E; Larratt Loree M; Skotnicki Aleksander B; Koziner Benjamin; Chanan-Khan Asher A; Seymour John F; Gribben John; Itri Loretta M; Rai Kanti R
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5208-12.
2009: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Bueso-Ramos Carlos; Abruzzo Lynne; Pierce Sherry; Shan Jianqin; Issa Jean-Pierre; Garcia-Manero Guillermo
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Thomas Deborah A; O'Brien Susan; Kantarjian Hagop M
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.
Hematology/oncology clinics of North America 2009;23(5):949-71, v.
2009: Jain Nitin; Wierda William; Ferrajoli Alessandra; Wong Franklin; Lerner Susan; Keating Michael; O'Brien Susan
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
Cancer 2009;115(19):4533-9.
2009: Jabbour Elias; Jones Daniel; Kantarjian Hagop M; O'Brien Susan; Tam Constantine; Koller Charles; Burger Jan A; Borthakur Gautam; Wierda William G; Cortes Jorge
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Blood 2009;114(10):2037-43.
2009: Quintás-Cardama Alfonso; De Souza Santos Fabio Pires; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Awais Ahmed; Borthakur Gautam; Cortes Jorge
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Cancer 2009;115(17):3935-43.
2009: Alvarado Yesid; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Borthakur Gautam; Burger Jan; Wierda William; Garcia-Manero Guillermo; Shan Jianqin; Cortes Jorge
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Cancer 2009;115(16):3709-18.
2009: Kantarjian Hagop M; Shan Jianqin; Jones Daniel; O'Brien Susan; Rios Mary Beth; Jabbour Elias; Cortes Jorge
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3659-63.
2009: Borthakur Gautam; Lin E; Jain Nitin; Estey Elihu E; Cortes Jorge E; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Pierce Sherry; Kantarjian Hagop
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: Tam Constantine S; Shanafelt Tait D; Wierda William G; Abruzzo Lynne V; Van Dyke Daniel L; O'Brien Susan; Ferrajoli Alessandra; Lerner Susan A; Lynn Alice; Kay Neil E; Keating Michael J
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Blood 2009;114(5):957-64.
2009: Quintás-Cardama Alfonso; Cortes Jorge E; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Liu David; Bleickardt Eric; Chen Tai-Tsang; Kantarjian Hagop M
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: Quintás-Cardama Alfonso; Kantarjian Hagop; Ravandi Farhad; O'Brien Susan; Thomas Deborah; Vidal-Senmache Gabriela; Wierda William; Kornblau Steven; Cortes Jorge
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer 2009;115(11):2482-90.
2009: Garg Ravin; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Ravandi Farhad; Lovshe Denise; Pierce Sherry; O'Brien Susan
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Cancer 2009;115(10):2147-54.
2009: Fava Carmen; Kantarjian Hagop M; Jabbour Elias; O'Brien Susan; Jain Nitin; Rios Mary Beth; Garcia-Manero Guillermo; Ravandi Farhad; Verstovsek Srdan; Borthakur Gautam; Shan Jianqin; Cortes Jorge
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Garcia-Manero Guillermo; Cortes Jorge; Thomas Deborah; Koller Charles; Burger Jan; Lerner Susan; Kantarjian Hagop; Keating Michael
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1637-43.
2009: Lin Katherine I; Tam Constantine S; Keating Michael J; Wierda William G; O'Brien Susan; Lerner Susan; Coombes Kevin R; Schlette Ellen; Ferrajoli Alessandra; Barron Lynn L; Kipps Thomas J; Rassenti Laura; Faderl Stefan; Kantarjian Hagop; Abruzzo Lynne V
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood 2009;113(14):3168-71.
2009: Tsimberidou Apostolia-Maria; Wen Sijin; McLaughlin Peter; O'Brien Susan; Wierda William G; Lerner Susan; Strom Sara; Freireich Emil J; Medeiros L Jeffrey; Kantarjian Hagop M; Keating Michael J
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):904-10.
2009: Ravandi Farhad; Estey Eli; Jones Dan; Faderl Stefan; O'Brien Susan; Fiorentino Jackie; Pierce Sherry; Blamble Deborah; Estrov Zeev; Wierda William; Ferrajoli Alessandra; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Quintás-Cardama Alfonso; O'Brien Susan
Targeted therapy for chronic lymphocytic leukemia.
Targeted oncology 2009;4(1):11-21.
2009: Tsimberidou Apostolia-Maria; Tam Constantine; Abruzzo Lynne V; O'Brien Susan; Wierda William G; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):373-80.
2009: Verma Dushyant; O'Brien Susan; Thomas Deborah; Faderl Stefan; Koller Charles; Pierce Sherry; Kebriaei Partow; Garcia-Manero Guillermo; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer 2009;115(1):101-6.
2008: Inamdar Kedar V; O'Brien Susan; Sen Subrata; Keating Michael; Nguyen Martin H; Wang Xuemei; Fernandez Michael; Thomazy Vilmos; Medeiros L Jeffrey; Bueso-Ramos Carlos E
Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008;21(12):1428-35.
2008: O'Brien Susan; Thomas Deborah; Ravandi Farhad; Faderl Stefan; Cortes Jorge; Borthakur Gautum; Pierce Sherry; Garcia-Manero Guillermo; Kantarjian Hagop M
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Wierda William; Faderl Stefan; Garcia-Manero Guillermo; Issa Jean-Pierre; Estey Elihu; Keating Michael; Freireich Emil J
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Cancer 2008;113(7 Suppl):1933-52.
2008: O'Brien Susan; Thomas Deborah A; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Kantarjian Hagop
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
Cancer 2008;113(8):2097-101.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; Keating Michael J; O'Brien Susan; Brandt Mark; Pierce Sherry; Freireich Emil J; Medeiros L Jeffrey; Estey Elihu
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Cancer 2008;113(6):1370-8.
2008: Kantarjian Hagop; O'Brien Susan; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Bennett John M; List Alan; Fenaux Pierre; Sanz Guillermo; Issa Jean-Pierre; Freireich Emil J; Garcia-Manero Guillermo
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Jones Dan; Thomas Deborah; Yin C Cameron; O'Brien Susan; Cortes Jorge E; Jabbour Elias; Breeden Megan; Giles Francis J; Zhao Weiqiang; Kantarjian Hagop M
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Vega-Ruiz Arturo; O'Brien Susan; Cortes Jorge; Kebriaei Partow; Thomas Deborah; Kantarjian Hagop; Ravandi Farhad
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Leukemia research 2008;32(9):1468-71.
2008: Tam Constantine S; Kantarjian Hagop; Garcia-Manero Guillermo; Borthakur Gautam; O'Brien Susan; Ravandi Farhad; Shan Jenny; Cortes Jorge
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Tam Constantine S; O'Brien Susan; Wierda William; Kantarjian Hagop; Wen Sijin; Do Kim-Anh; Thomas Deborah A; Cortes Jorge; Lerner Susan; Keating Michael J
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood 2008;112(4):975-80.
2008: Safdar Amar; Rodriguez Gilhen H; Rueda Adriana M; Wierda William G; Ferrajoli Alessandra; Musher Daniel M; O'Brien Susan; Koller Charles A; Bodey Gerald P; Keating Michael J
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.
Cancer 2008;113(2):383-7.
2008: Jabbour Elias; Kantarjian Hagop; Jones Dan; Breeden Megan; Garcia-Manero Guillermo; O'Brien Susan; Ravandi Farhad; Borthakur Gautam; Cortes Jorge
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood 2008;112(1):53-5.
2008: Verstovsek Srdan; Tefferi Ayalew; Cortes Jorge; O'Brien Susan; Garcia-Manero Guillermo; Pardanani Animesh; Akin Cem; Faderl Stefan; Manshouri Taghi; Thomas Deborah; Kantarjian Hagop
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Tam Constantine S; Otero-Palacios Joselle; Abruzzo Lynne V; Jorgensen Jeffrey L; Ferrajoli Alessandra; Wierda William G; Lerner Susan; O'Brien Susan; Keating Michael J
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
British journal of haematology 2008;141(1):36-40.
2008: Gandhi Varsha; Tam Constantine; O'Brien Susan; Jewell Roxanne C; Rodriguez Carlos O; Lerner Susan; Plunkett William; Keating Michael J
Phase I trial of nelarabine in indolent leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1098-105.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; O'Brien Susan; Cortes Jorge; Wierda William G; Koller Charles; Pierce Sherry; Brandt Mark; Freireich Emil J; Keating Michael J; Estey Elihu H
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Kantarjian Hagop; O'Brien Susan; Shan Jianqin; Huang Xuelin; Garcia-Manero Guillermo; Faderl Stefan; Ravandi-Kashani Farhad; Verstovsek Srdan; Beth Rios Mary; Cortes Jorge
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2008: Tsimberidou Apostolia M; Wierda William G; Plunkett William; Kurzrock Razelle; O'Brien Susan; Wen Sijin; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Garcia-Manero Guillermo; Estrov Zeev; Kipps Thomas J; Brown Jennifer R; Fiorentino Albert; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2008: Jabbour Elias; Cortes Jorge E; Ghanem Hady; O'Brien Susan; Kantarjian Hagop M
Targeted therapy in chronic myeloid leukemia.
Expert review of anticancer therapy 2008;8(1):99-110.
2007: Borthakur Gautam; Lin E; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Giles Francis; Browning Mary L; Kantarjian Hagop; Keating Michael; O'Brien Susan
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Cortes Jorge; Jabbour Elias; Kantarjian Hagop; Yin C Cameron; Shan Jianqin; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Breeden Megan; Reeves Nubia; Wierda William G; Jones Dan
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: O'Brien Susan
Expert perspectives on advances in hematologic malignancies.
Clinical advances in hematology & oncology : H&O 2007;5(11):865-6, 919.
2007: Cortes Jorge; Quintás-Cardama Alfonso; Garcia-Manero Guillermo; O'Brien Susan; Jones Dan; Faderl Stefan; Ebarb Theresa; Giles Francis; Thomas Deborah; Kantarjian Hagop
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Atallah Ehab; Cortes Jorge; O'Brien Susan; Pierce Sherry; Rios Mary Beth; Estey Elihu; Markman Maurie; Keating Michael; Freireich Emil J; Kantarjian Hagop
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
2007: Tsimberidou Apostolia M; Wen Sijin; O'Brien Susan; McLaughlin Peter; Wierda William G; Ferrajoli Alessandra; Faderl Stefan; Manning John; Lerner Susan; Mai Chinh V; Rodriguez Alma M; Hess Mark; Do Kim-Anh; Freireich Emil J; Kantarjian Hagop M; Medeiros L Jeffrey; Keating Michael J
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Tam Constantine S; O'Brien Susan; Lerner Susan; Khouri I; Ferrajoli A; Faderl S; Browning M; Tsimberidou Apostolia M; Kantarjian Hagop; Wierda William G
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.
Leukemia & lymphoma 2007;48(10):1931-9.
2007: Jabbour Elias; Kantarjian Hagop M; Abruzzo Lynne V; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; O'brien Susan; Borthakur Gautham; Bruzzi John; Munden Reginald; Cortes Jorge
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3908-14.
2007: Abruzzo Lynne V; Barron Lynn L; Anderson Keith; Newman Rachel J; Wierda William G; O'brien Susan; Ferrajoli Alessandra; Luthra Madan; Talwalkar Sameer; Luthra Rajyalakshmi; Jones Dan; Keating Michael J; Coombes Kevin R
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.
The Journal of molecular diagnostics : JMD 2007;9(4):546-55.
2007: Cortes Jorge; Jabbour Elias; Daley George Q; O'Brien Susan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Zhu Yali; Statkevich Paul; Kantarjian Hagop
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cancer 2007;110(6):1295-302.
2007: Yanada Masamitsu; Huang Xuelin; Garcia-Manero Guillermo; O'brien Susan; Ravandi Farhad; Borthakur Gautam; Faderl Stefan; Issa Jean-Pierre; Kantarjian Hagop; Estey Elihu
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Jabbour Elias; Cortes Jorge; Giles Francis; O'Brien Susan; Kantarijan Hagop
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
IDrugs : the investigational drugs journal 2007;10(7):468-79.
2007: Aribi Ahmed; Bueso-Ramos Carlos; Estey Eli; Estrov Zeev; O'Brien Susan; Giles Francis; Faderl Stefan; Thomas Deborah; Kebriaei Partow; Garcia-Manero Guillermo; Pierce Sherry; Cortes Jorge; Kantarjian Hagop; Ravandi Farhad
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Espandar Ladan; O'Brien Susan; Thirkill Charles; Lubecki Linda A; Esmaeli Bita
Successful treatment of cancer-associated retinopathy with alemtuzumab.
Journal of neuro-oncology 2007;83(3):295-302.
2007: Aribi Ahmed; Huh Yang; Keating Michael; O'brien Susan; Ferrajoli Alessandra; Faderl Stefan; Wierda William; Kantarjian Hagop; Ravandi Farhad
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Leukemia research 2007;31(7):939-45.
2007: Jabbour Elias; Cortes Jorge E; Giles Francis J; O'Brien Susan; Kantarjian Hagop M
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: Wierda William G; O'Brien Susan; Wang Xuemei; Faderl Stefan; Ferrajoli Alessandra; Do Kim-Anh; Cortes Jorge; Thomas Deborah; Garcia-Manero Guillermo; Koller Charles; Beran Miloslav; Giles Francis; Ravandi Farhad; Lerner Susan; Kantarjian Hagop; Keating Michael
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Khouri Issa F; Saliba Rima M; Admirand Joan; O'Brien Susan; Lee Ming-S; Korbling Martin; Samuels Barry I; Giralt Sergio; Lima de Marcos; Keating Michael J; Champlin Richard E; Bueso-Ramos Carlos
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
British journal of haematology 2007;137(4):355-63.
2007: Kantarjian Hagop; O'Brien Susan; Talpaz Moshe; Borthakur Gautam; Ravandi Farhad; Faderl Stefan; Verstovsek Srdan; Rios Mary Beth; Shan Jianqin; Giles Francis; Cortes Jorge
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Jabbour Elias; O'Brien Susan; Kantarjian Hagop; Garcia-Manero Guillermo; Ferrajoli Alessandra; Ravandi Farhad; Cabanillas Maria; Thomas Deborah A
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood 2007;109(8):3214-8.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Rios Mary Beth; Giles Francis; Kantarjian Hagop
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S51-7.
2007: Borthakur Gautam; O'Brien Susan; Wierda William G; Thomas Deborah A; Cortes Jorge E; Giles Francis J; Kantarjian Hagop M; Lerner Susan; Keating Michael J
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Kantarjian Hagop M; O'Brien Susan; Huang Xuelin; Garcia-Manero Guillermo; Ravandi Farhad; Cortes Jorge; Shan Jianqin; Davisson Jan; Bueso-Ramos Carlos E; Issa Jean-Pierre
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: O'Brien Susan; Moore Joseph O; Boyd Thomas E; Larratt Loree M; Skotnicki Aleksander; Koziner Benjamin; Chanan-Khan Asher A; Seymour John F; Bociek R Gregory; Pavletic Steve; Rai Kanti R
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1114-20.
2007: Oki Yasuhiro; Kantarjian Hagop M; Gharibyan Vazganush; Jones Dan; O'brien Susan; Verstovsek Srdan; Cortes Jorge; Morris Gail M; Garcia-Manero Guillermo; Issa Jean-Pierre J
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Cancer 2007;109(5):899-906.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Ravandi Farhad; Giles Francis; Thomas Deborah; Wierda William; Cortes Jorge
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Jabbour Elias; Cortes Jorge; O'Brien Susan; Giles Francis; Kantarjian Hagop
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Seminars in hematology 2007;44(1 Suppl 1):S25-31.
2007: Quintás-Cardama Alfonso; Kantarjian Hagop; Garcia-Manero Guillermo; O'Brien Susan; Faderl Stefan; Estrov Zeev; Giles Francis; Murgo Anthony; Ladie Nakia; Verstovsek Srdan; Cortes Jorge
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Giles Francis; Rizzieri David; Karp Judith; Vey Norbert; Ravandi Farhad; Faderl Stefan; Khan Khuda Dad; Verhoef Gregor; Wijermans Pierre; Advani Anjali; Roboz Gail; Kantarjian Hagop; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon M G J; Karsten Verena; Cahill Ann; Albitar Maher; Mufti Ghulam; O'Brien Susan
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Kantarjian Hagop M; O'Brien Susan; Shan Jianqin; Aribi Ahmed; Garcia-Manero Guillermo; Jabbour Elias; Ravandi Farhad; Cortes Jorge; Davisson Jan; Issa Jean-Pierre
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2007: Quintas-Cardama Alfonso; Kantarjian Hagop; Jones Dan; Nicaise Claude; O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2007: Kantarjian Hagop; Oki Yasuhiro; Garcia-Manero Guillermo; Huang Xuelin; O'Brien Susan; Cortes Jorge; Faderl Stefan; Bueso-Ramos Carlos; Ravandi Farhad; Estrov Zeev; Ferrajoli Alessandra; Wierda William; Shan Jianqin; Davis Jan; Giles Francis; Saba Hussain I; Issa Jean-Pierre J
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2006: Kantarjian Hagop M; Talpaz Moshe; Giles Francis; O'Brien Susan; Cortes Jorge
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Giles Francis; Verstovsek Srdan; Faderl Stefan; Vey Norbert; Karp Judy; Roboz Gail; Khan Khuda Dan; Cooper Maureen; Bilgrami Syed Fazl Ali; Ferrant Augustin; Daenen Simon; Karsten Verena; Cahill Ann; Albitar Maher; Kantarjian Hagop; O'Brien Susan; Feldman Eric
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Ravandi Farhad; O'brien Susan
Alemtuzumab in CLL and other lymphoid neoplasms.
Cancer investigation 2006;24(7):718-25.
2006: Garcia-Manero Guillermo; Kantarjian Hagop M; Sanchez-Gonzalez Blanca; Yang Hui; Rosner Gary; Verstovsek Srdan; Rytting Michael; Wierda William G; Ravandi Farhad; Koller Charles; Xiao Lianchun; Faderl Stefan; Estrov Zeev; Cortes Jorge; O'brien Susan; Estey Elihu; Bueso-Ramos Carlos; Fiorentino Jackie; Jabbour Elias; Issa Jean-Pierre
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Jabbour Elias; Giles Francis; Ravandi Farhad; Faderl Stefan; Pierce Sherry; Shan Jenny; Verstovsek Srdan; Cortes Jorge
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios M B; Verstovsek S; Cortes J
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(10):1767-73.
2006: Yee Karen W L; Zeng Zhihong; Konopleva Marina; Verstovsek Srdan; Ravandi Farhad; Ferrajoli Alessandra; Thomas Deborah; Wierda William; Apostolidou Efrosyni; Albitar Maher; O'Brien Susan; Andreeff Michael; Giles Francis J
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5165-73.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Kantarjian Hagop M; Koller Charles; Hagemeister Fredrick B; Fayad Luis; Lerner Susan; Bueso-Ramos Carlos E; Keating Michael J
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Faderl Stefan; Rai Kanti; Gribben John; Byrd John C; Flinn Ian W; O'Brien Susan; Sheng Shihong; Esseltine Dixie-Lee; Keating Michael J
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cancer 2006;107(5):916-24.
2006: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Jones Daniel; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Ravandi Farhad; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Koller Charles; Bekele B Nebiyou; Zhou Xian; Park Charles; Estrov Zeev; O'Brien Susan; Keating Michael; Jilani Iman; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
Blood 2006;108(3):1001-6.
2006: Kojima Kensuke; Konopleva Marina; McQueen Teresa; O'Brien Susan; Plunkett William; Andreeff Michael
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Blood 2006;108(3):993-1000.
2006: Giles Francis; Verstovsek Srdan; Garcia-Manero Guillermo; Thomas Deborah; Ravandi Farhad; Wierda William; Ferrajoli Alessandra; Kornblau Steve; Jabbour Elias; Shan Jianqin; O'brien Susan; Albitar Maher; Kantarjian Hagop
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Tsimberidou Apostolia M; Catovsky Daniel; Schlette Ellen; O'Brien Susan; Wierda William G; Kantarjian Hagop; Garcia-Manero Guillermo; Wen Sijin; Do Kim-Anh; Lerner Susan; Keating Michael J
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Cancer 2006;107(1):125-35.
2006: Faderl Stefan; Verstovsek Srdan; Cortes Jorge; Ravandi Farhad; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; O'Brien Susan; Koller Charles; Giles Francis J; Wierda William; Kwari Monica; Kantarjian Hagop M
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Tsimberidou Apostolia-Maria; Tirado-Gomez Maribel; Andreeff Michael; O'Brien Susan; Kantarjian Hagop; Keating Michael; Lopez-Berestein Gabriel; Estey Elihu
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Leukemia & lymphoma 2006;47(6):1062-8.
2006: Kantarjian Hagop; Giles Francis; Wunderle Lydia; Bhalla Kapil; O'Brien Susan; Wassmann Barbara; Tanaka Chiaki; Manley Paul; Rae Patricia; Mietlowski William; Bochinski Kathy; Hochhaus Andreas; Griffin James D; Hoelzer Dieter; Albitar Maher; Dugan Margaret; Cortes Jorge; Alland Leila; Ottmann Oliver G
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Talpaz Moshe; Shah Neil P; Kantarjian Hagop; Donato Nicholas; Nicoll John; Paquette Ron; Cortes Jorge; O'Brien Susan; Nicaise Claude; Bleickardt Eric; Blackwood-Chirchir M Anne; Iyer Vishwanath; Chen Tai-Tsang; Huang Fei; Decillis Arthur P; Sawyers Charles L
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
The New England journal of medicine 2006;354(24):2531-41.
2006: Tibes Raoul; Keating Michael J; Ferrajoli Alessandra; Wierda William; Ravandi Farhad; Garcia-Manero Guillermo; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Browning Mary L; Faderl Stefan
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: O'Brien Susan
Practical applications of measuring and monitoring MRD in patients with CLL.
Clinical advances in hematology & oncology : H&O 2006;4(5):8-9; discussion 10; suppl 12.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Khouri Issa; Giles Francis J; Kantarjian Hagop M; Champlin Richard; Wen Sijin; Do Kim-Anh; Smith Susan C; Lerner Susan; Freireich Emil J; Keating Michael J
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Cortes Jorge E; Talpaz Moshe; O'Brien Susan; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Rios Mary B; Shan Jenny; Kantarjian Hagop M
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Ault Patricia; Kantarjian Hagop; O'Brien Susan; Faderl Stefan; Beran Miloslav; Rios Mary Beth; Koller Charles; Giles Francis; Keating Michael; Talpaz Moshe; Cortes Jorge
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Kantarjian Hagop; Beran Miloslav; Cortes Jorge; O'Brien Susan; Giles Francis; Pierce Sherry; Shan Jianqin; Plunkett William; Keating Michael; Estey Elihu
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Kantarjian Hagop; O'brien Susan; Cortes Jorge; Giles Francis; Faderl Stefan; Jabbour Elias; Garcia-Manero Guillermo; Wierda William; Pierce Sherry; Shan Jianqin; Estey Elihu
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Tsimberidou Apostolia-Maria; Giles Francis J; Estey Elihu; O'Brien Susan; Keating Michael J; Kantarjian Hagop M
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Ravandi Farhad; O'Brien Susan
Immune defects in patients with chronic lymphocytic leukemia.
Cancer immunology, immunotherapy : CII 2006;55(2):197-209.
2006: Mattiuzzi Gloria N; Alvarado Gladys; Giles Francis J; Ostrosky-Zeichner Luis; Cortes Jorge; O'brien Susan; Verstovsek Srdan; Faderl Stefan; Zhou Xian; Raad Issam I; Bekele B Nebiyou; Leitz G J; Lopez-Roman Ivonne; Estey Elihu H
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Wierda William; O'brien Susan; Faderl Stefan; Ferrajoli Alessandra; Wang Xuemei; Do Kim-Anh; Garcia-Manero Guillermo; Thomas Deborah; Cortes Jorge; Ravandi-Kashani Farhad; Giles Francis; Lerner Susan; Kantarjian Hagop; Keating Michael
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Borthakur Gautam; Kantarjian Hagop; Daley George; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Faderl Stefan; Sugrue Mary; Cortes Jorge
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Thomas Deborah A; Sarris Andreas H; Cortes Jorge; Faderl Stefan; O'Brien Susan; Giles Francis J; Garcia-Manero Guillermo; Rodriguez Maria A; Cabanillas Fernando; Kantarjian Hagop
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Jabbour Elias; Kantarjian Hagop; O'Brien Susan; Rios Mary Beth; Abruzzo Lynne; Verstovsek Srdan; Garcia-Manero Guillermo; Cortes Jorge
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Blood 2006;107(2):480-2.
2006: Faderl Stefan; O'Brien Susan; Keating Michael J
Monoclonal antibody combinations in CLL: evolving strategies.
Best practice & research. Clinical haematology 2006;19(4):781-93.
2005: Ravandi Farhad; O'Brien Susan
Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(12):1660-74.
2005: Faderl Stefan; Do Kim-Anh; Johnson Marcella M; Keating Michael; O'brien Susan; Jilani Iman; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Aguilar Christine; Dey Amanda; Thomas Deborah A; Giles Francis J; Kantarjian Hagop M; Albitar Maher
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Ravandi Farhad; O'Brien Susan; Jones Dan; Lerner Susan; Faderl Stefan; Ferrajoli Alessandra; Wierda William; Garcia-Manero Guillermo; Thomas Deborah; Koller Charles; Verstovsek Srdan; Giles Francis; Cortes Jorge; Herling Marco; Kantarjian Hagop; Keating Michael
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: O'Brien Susan; Albitar Maher; Giles Francis J
Monoclonal antibodies in the treatment of leukemia.
Current molecular medicine 2005;5(7):663-75.
2005: Giles Francis; Verstovsek Srdan; Thomas Deborah; Gerson Stanton; Cortes Jorge; Faderl Stefan; Ferrajoli Alessandra; Ravandi Farhad; Kornblau Steven; Garcia-Manero Guillermo; Jabbour Elias; O'Brien Susan; Karsten Verena; Cahill Ann; Yee Karen; Albitar Maher; Sznol Mario; Kantarjian Hagop
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Ravandi Farhad; Kantarjian Hagop; Jones Dan; Dearden Claire; Keating Michael; O'Brien Susan
Mature T-cell leukemias.
Cancer 2005;104(9):1808-18.
2005: Talpaz Moshe; Rakhit Ashok; Rittweger Karen; O'Brien Susan; Cortes Jorge; Fettner Scott; Hooftman Leon; Kantarjian Hagop
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6247-55.
2005: Ravandi Farhad; O'Brien Susan
Infections associated with purine analogs and monoclonal antibodies.
Blood reviews 2005;19(5):253-73.
2005: Georgakis Georgios V; Li Yang; Humphreys Robin; Andreeff Michael; O'Brien Susan; Younes Mamoun; Carbone Antonino; Albert Vivian; Younes Anas
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
British journal of haematology 2005;130(4):501-10.
2005: Jabbour Elias; Verstovsek Srdan; Giles Francis; Gandhi Varsha; Cortes Jorge; O'Brien Susan; Plunkett William; Garcia-Manero Guillermo; Jackson C Ellen; Kantarjian Hagop; Andreeff Michael
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Giles Francis; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Bueso-Ramos Carlos; Shan Jianqin; Pierce Sherry; Garcia-Manero Guillermo; Keating Michael; Kantarjian Hagop
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Wierda William; Rios Mary Beth; Shan Jianqin; Cortes Jorge
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Kantarjian Hagop M; Bueso-Ramos Carlos E; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Shan Jianqin; Cortes Jorge
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Saba Rashid; Jabbour Elias; Giles Francis; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Freireich Emil J; Garcia-Manero Guillermo; Kantarjian Hagop; Verstovsek Srdan
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Wierda William; O'Brien Susan; Wen Sijin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah; Do Kim-Anh; Cortes Jorge; Koller Charles; Beran Miloslav; Ferrajoli Alessandra; Giles Francis; Lerner Susan; Albitar Maher; Kantarjian Hagop; Keating Michael
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Jones Dan; Luthra Rajyalakshmi; Shan Jenny; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Rios Mary B; Kantarjian Hagop
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Shan Jianqin; Rios Mary Beth; Champlin Richard; de Lima Marcos; Cortes Jorge
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Cortes Jorge; Faderl Stefan; Estey Elihu; Kurzrock Razelle; Thomas Deborah; Beran Miloslav; Garcia-Manero Guillermo; Ferrajoli Alessandra; Giles Francis; Koller Charles; O'Brien Susan; Wright John; Bai Stephen A; Kantarjian Hagop
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Quintas-Cardama Alfonso; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Rios Mary Beth; Hayes Kimberly; Glassman Armand; Bekele B Nebiyou; Zhou Xian; Cortes Jorge
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Blood 2005;105(6):2281-6.
2005: Ravandi Farhad; O'Brien Susan
Alemtuzumab.
Expert review of anticancer therapy 2005;5(1):39-51.
2005: Estey Elihu; Koller Charles; Tsimberidou Apostolia M; O'Brien Susan; Beran Miloslav; Cortes Jorge; Tirado-Gomez Maribel; Lopez-Berestein Gabriel; Kantarjian Hagop
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.
Blood 2005;105(3):1366-7.
2005: Faderl Stefan; Gandhi Varsha; O'Brien Susan; Bonate Peter; Cortes Jorge; Estey Elihu; Beran Miloslav; Wierda William; Garcia-Manero Guillermo; Ferrajoli Alessandra; Estrov Zeev; Giles Francis J; Du Min; Kwari Monica; Keating Michael; Plunkett William; Kantarjian Hagop
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2004: Kantarjian Hagop; Thomas Deborah; O'Brien Susan; Cortes Jorge; Giles Francis; Jeha Sima; Bueso-Ramos Carlos E; Pierce Sherry; Shan Jianqin; Koller Charles; Beran Miloslav; Keating Michael; Freireich Emil J
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Hennessy Bryan; Giles Francis; Cortes Jorge; O'brien Susan; Ferrajoli Alessandra; Ossa Gladys; Garcia-Manero Guillermo; Faderl Stefan; Kantarjian Hagop; Verstovsek Srdan
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Luthra Rajyalakshmi; Giles Francis; Verstovsek Srdan; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Jones Dan; Talpaz Moshe
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Bueso-Ramos Carlos E; Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; Medeiros L Jeffrey; Kantarjian Hagop
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Verstovsek Srdan; Giles Francis J; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Quintas-Cardama Alfonso; Kantarjian Hagop; O'Brien Susan; Garcia-Manero Guillermo; Rios Mary B; Talpaz Moshe; Cortes Jorge
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
Cancer 2004;100(12):2592-7.
2004: Tsimberidou Apostolia M; Keating Michael J; Giles Francis J; Wierda William G; Ferrajoli Alessandra; Lerner Susan; Beran Miloslav; Andreeff Michael; Kantarjian Hagop M; O'Brien Susan
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Cortes Jorge; O'Brien Susan; Quintas Alfonso; Giles Francis; Shan Jianquin; Rios Mary Beth; Talpaz Moshe; Kantarjian Hagop
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Tsimberidou Apostolia-Maria; Murray James L; O'Brien Susan; Wierda William G; Keating Michael J
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Cancer 2004;100(10):2195-200.
2004: Ma Yupo; Mansour Adnan; Bekele B Nebiyou; Zhou Xian; Keating Michael J; O'Brien Susan; Giles Francis J; Albitar Maher
The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.
Cancer 2004;100(10):2167-75.
2004: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Verstovsek Srdan; Giles Francis; Rios Mary Beth; Shan Jianqin; Letvak Laurie; Thomas Deborah; Faderl Stefan; Ferrajoli Alessandra; Cortes Jorge
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Mattiuzzi Gloria N; Kantarjian Hagop; O'Brien Susan; Kontoyiannis Dimitrios P; Giles Francis; Zhou Xian; Lim JoAnn; Bekele B Nebiyou; Faderl Stefan; Cortes Jorge; Pierce Sherry; Leitz Gerhard J; Raad Issam; Estey Elihu
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Shan Jianqin; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Wierda William; Kornblau Steven; Ferrajoli Alessandra; Keating Michael; Talpaz Moshe
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Sneed Thomas B; Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Rios Mary Beth; Bekele B Nebiyou; Zhou Xian; Resta Debra; Wierda William; Faderl Stefan; Giles Francis; Cortes Jorge E
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2004: Liu Nina Shih; O'Brien Susan
Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Medical oncology (Northwood, London, England) 2004;21(4):297-304.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Keating Michael; Talpaz Moshe
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Tsao Anne S; Kantarjian Hagop; Cortes Jorge; O'Brien Susan; Talpaz Moshe
Imatinib mesylate causes hypopigmentation in the skin.
Cancer 2003;98(11):2483-7.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Giles Francis; Estey Elihu; O'Brien Susan
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Cancer 2003;98(10):2095-104.
2003: Medina Jorge; Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Garcia-Manero Guillermo; Giles Francis; Rios Mary Beth; Hayes Kimberly; Cortes Jorge
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Jilani Iman; O'Brien Susan; Manshuri Taghi; Thomas Deborah A; Thomazy Vilmos A; Imam Maha; Naeem Sana; Verstovsek Srdan; Kantarjian Hagop; Giles Francis; Keating Michael; Albitar Maher
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Blood 2003;102(10):3514-20.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorges; Shan Jianqin; Giles Francis; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Rios Mary Beth; Talpaz Moshe
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Lee Jeong N; Giles Fancis; Huh Yang O; Manshouri Taghi; O'Brien Susan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Beran Miloslav; O'Brien Susan; Thomas Deborah A; Tran Hai T; Cortes-Franco Jorge E; Giles Francis; Estey Elihu; Kantarjian Hagop M
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: Cortes Jorge; Talpaz Moshe; O'Brien Susan; Giles Francis; Beth Rios Mary; Shan Jianquin; Faderl Stefan; Garcia-Manero Guillermo; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: O'Brien Susan; Giles Francis; Talpaz Moshe; Cortes Jorge; Rios Mary Beth; Shan Jianqin; Thomas Deborah; Andreeff Michael; Kornblau Steven; Faderl Stefan; Garcia-Manero Guillermo; White Kevin; Mallard Susie; Freireich Emil; Kantarjian Hagop M
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Issa Jean-Pierre; Garcia-Manero Guillermo; Rios Mary Beth; Shan Jianqin; Andreeff Michael; Keating Michael; Talpaz Moshe
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Garcia-Manero Guillermo; Faderl Stefan; O'Brien Susan; Cortes Jorge; Talpaz Moshe; Kantarjian Hagop M
Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Cancer 2003;98(3):437-57.
2003: O'Brien Susan; Giles Francis J
Monoclonal antibodies in the treatment of lymphoid leukemia.
Drugs of today (Barcelona, Spain : 1998) 2003;39(7):541-50.
2003: Konopleva Marina; Cheng Su-Chun; Cortes Jorge E; Hayes Kimberly J; Pierce Sherry A; Andreeff Michael; Giles Francis J; O'Brien Susan; Kantarjian Hagop M; Estey Elihu H
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Kantarjian Hagop; O'Brien Susan; Cortes Jorge; Giles Francis; Thomas Deborah; Kornblau Steven; Shan Jianquin; Beth Rios Mary; Keating Michael; Freireich Emil; Talpaz Moshe
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Garcia-Manero Guillermo; Rios Mary Beth; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Freireich Emil J; Talpaz Moshe; Kantarjian Hagop
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Garcia-Manero Guillermo; Talpaz Moshe; Giles Francis J; Cortes Jorge; Faderl Stefan; O'Brien Susan; Thomas Deborah; Verstovsek Srdan; Beth Rios Mary; Shan Jianquin; Ferrajoli Alessandra; Wierda William; Kantarjian Hagop M
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Cortes Jorge; Giles Francis; O'Brien Susan; Thomas Deborah; Albitar Maher; Rios Mary Beth; Talpaz Moshe; Garcia-Manero Guillermo; Faderl Stefan; Letvak Laurie; Salvado August; Kantarjian Hagop
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: Giles Francis J; Bekele B Nebiyou; O'Brien Susan; Cortes Jorge E; Verstovsek Srdan; Balerdi Maria; Yared Marwan; Zhou Xian; Kantarjian Hagop M; Keating Michael J; Thall Peter; Albitar Maher
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Giles Francis J; Kantarjian Hagop M; Cortes Jorge E; Garcia-Manero Guillermo; Verstovsek Srdan; Faderl Stefan; Thomas Deborah A; Ferrajoli Alessandra; O'Brien Susan; Wathen Jay K; Xiao Lian-Chun; Berry Donald A; Estey Elihu H
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Kantarjian Hagop; Talpaz Moshe; O'Brien Susan; Giles Francis; Rios Mary Beth; White Kevin; Garcia-Manero Guillermo; Ferrajoli Alessandra; Verstovsek Srdan; Wierda William; Kornblau Steven; Cortes Jorge
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Lazo Guillermo; Kantarjian Hagop; Estey Elihu; Thomas Deborah; O'Brien Susan; Cortes Jorge
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Cancer 2003;97(9):2218-24.
2003: Cortes Jorge E; Talpaz Moshe; Giles Francis; O'Brien Susan; Rios Mary Beth; Shan Jianqin; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah A; Wierda William; Ferrajoli Allessandra; Jeha Sima; Kantarjian Hagop M
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Kantarjian Hagop M; Gandhi Varsha; Kozuch Peter; Faderl Stefan; Giles Francis; Cortes Jorge; O'Brien Susan; Ibrahim Nuhad; Khuri Fadlo; Du Min; Rios Mary Beth; Jeha Sima; McLaughlin Peter; Plunkett William; Keating Michael
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Tsimberidou Apostolia; Estey Elihu; Cortes Jorge; Thomas Deborah; Faderl Stefan; Verstovsek Srdan; Garcia-Manero Guillermo; Keating Michael; Albitar Maher; O'Brien Susan; Kantarjian Hagop; Giles Francis
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Cortes Jorge; Kantarjian Hagop; Albitar Maher; Thomas Deborah; Faderl Stefan; Koller Charles; Garcia-Manero Guillermo; Giles Francis; Andreeff Michael; O'Brien Susan; Keating Michael; Estey Elihu
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Cortes Jorge; Albitar Maher; Thomas Deborah; Giles Francis; Kurzrock Razelle; Thibault Alain; Rackoff Wayne; Koller Charles; O'Brien Susan; Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Wierda William G; Johnson Marcella M; Do Kim-Anh; Manshouri Taghi; Dey Amanda; O'Brien Susan; Giles Francis J; Kantarjian Hagop; Thomas Deborah; Faderl Stefan; Lerner Susan; Keating Michael; Albitar Maher
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: O'Brien Susan;
Chronic myelogenous leukemia clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1 Suppl 1():S14-28.
2003: Kantarjian Hagop M; Cortes Jorge E; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Jeha Sima; Rios Mary Beth; Letvak Laurie; Bochinski Kathy; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2003: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Giles Francis; Garcia-Manero Guillermo; Faderl Stefan; Thomas Deborah; Shan Jianqin; Rios Mary Beth; Cortes Jorge
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2002: Liu Nina Shih; O'Brien Susan
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Leukemia & lymphoma 2002;43(12):2413-5.
2002: Aguayo Alvaro; Kantarjian Hagop M; Estey Elihu H; Giles Francis J; Verstovsek Srdan; Manshouri Taghi; Gidel Christy; O'Brien Susan; Keating Michael J; Albitar Maher
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Ueno Naoto T; Anagnostopoulos Athanasios; Rondón Gabriela; Champlin Richard E; Mikhailova N; Pankratova O S; Zoubarovskaya L S; Semenova E V; Afanasyev B V; O'Brien Susan; Andreeff Michael; Zaritskey Andrey Y
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.
British journal of haematology 2002;119(1):131-4.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Keating M J; O'Brien S; Kontoyiannis D; Plunkett W; Koller C; Beran M; Lerner S; Kantarjian H
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Lai Raymond; O'Brien Susan; Maushouri Taghi; Rogers Anna; Kantarjian Hagop; Keating Micheal; Albitar Maher
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
Cancer 2002;95(5):1071-5.
2002: Tsimberidou Apostolia-Maria; Thomas Deborah; O'Brien Susan; Andreeff Michael; Kurzrock Razelle; Keating Michael; Albitar Maher; Kantarjian Hagop; Giles Francis
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Cancer chemotherapy and pharmacology 2002;50(3):237-42.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Giralt Sergio A; Rios Mary Beth; Shan Jianqin; Giles Francis J; Thomas Deborah A; Faderl Stefan; De Lima Marcos; Garcia-Manero Guillermo; Champlin Richard; Arlinghaus Ralph; Talpaz Moshe
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Garcia-Manero Guillermo; Faderl Stefan; Giles Francis; Thomas Deborah; Cortes Jorge; O'Brien Susan; Davis Jan; Kantarjian Hagop M; Estey Elihu
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Ferrajoli Alessandra; Keating Michael J; Manshouri Taghi; Giles Francis J; Dey Amanda; Estrov Zeev; Koller Charles A; Kurzrock Razelle; Thomas Deborah A; Faderl Stefan; Lerner Susan; O'Brien Susan; Albitar Maher
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Kantarjian Hagop M; Talpaz Moshe; O'Brien Susan; Smith Terry L; Giles Francis J; Faderl Stefan; Thomas Deborah A; Garcia-Manero Guillermo; Issa Jean-Pierre J; Andreeff Michael; Kornblau Steven M; Koller Charles; Beran Milosav; Keating Michael; Rios Mary Beth; Shan Jenny; Resta Debra; Capdeville Renaud; Hayes Kimberly; Albitar Maher; Freireich Emil J; Cortes Jorge E
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Smith Terry L; Rios Mary Beth; Shan Jianqin; Yang Ying; Giles Francis J; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Jeha Sima; Wierda William; Issa Jean-Pierre J; Kornblau Steven M; Keating Michael; Resta Debra; Capdeville Renaud; Talpaz Moshe
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Atallah Ehab; Talpaz Moshe; O'brien Susan; Rios Mary Beth; Guo Jie Qiang; Arlinghaus Ralph; Fernandes-Reese Sofia; Kantarjian Hagop
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Cancer 2002;94(11):2996-9.
2002: Faderl S; Keating M J; Do K-A; Liang S-Y; Kantarjian H M; O'Brien S; Garcia-Manero G; Manshouri T; Albitar M
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(6):1045-52.
2002: Estey Elihu H; Giles Francis J; Beran Miloslav; O'Brien Susan; Pierce Sherry A; Faderl Stefan H; Cortes Jorge E; Kantarjian Hagop M
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Kantarjian Hagop M; Cortes Jorge; O'Brien Susan; Giles Francis J; Albitar Maher; Rios Mary Beth; Shan Jianqin; Faderl Stefan; Garcia-Manero Guillermo; Thomas Deborah A; Resta Debra; Talpaz Moshe
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Oudat R; Keating M J; Lerner S; O'Brien S; Albitar M
Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):632-5.
2002: O'Brien Susan; Talpaz Moshe; Cortes Jorge; Shan Jianqin; Giles Francis J; Faderl Stefan; Thomas Deborah; Garcia-Manero Guillermo; Mallard Susie; Beth Mary; Koller Charles; Kornblau Steve; Andreeff Michael; Murgo Anthony; Keating Michael; Kantarjian Hagop M
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Verstovsek Srdan; Kantarjian Hagop; Manshouri Taghi; O'Brien Susan; Faderl Stefan; Talpaz Moshe; Cortes Jorge; Albitar Maher
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2002: Cortes Jorge; Thomas Deborah; Rios Adan; Koller Charles; O'Brien Susan; Jeha Sima; Faderl Stefan; Kantarjian Hagop
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Cancer 2002;94(5):1492-9.
2002: Surapaneni Usha R; Cortes Jorge E; Thomas Deborah; O'Brien Susan; Giles Francis J; Koller Charles; Faderl Stefan; Kantarjian Hagop
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Keating Michael J; O'Brien Susan; Albitar Maher
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Seminars in oncology 2002;29(1 Suppl 2):70-4.
2002: Weiser Mary A; O'Brien Susan; Thomas Deborah A; Pierce Sherry A; Lam Tony P; Kantarjian Hagop M
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Cancer 2002;94(2):285-91.
2002: Giles Francis; Garcia-Manero Guillermo; O'Brien Susan; Estey Eihu; Kantarjian Hagop
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Acta haematologica 2002;108(3):164-7.
2001: Estey E H; Thall P F; Cortes J E; Giles F J; O'Brien S; Pierce S A; Wang X; Kantarjian H M; Beran M
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Kantarjian H M; Shan J; Smith T; Talpaz M; Kozuch P; Rios M B; Cortes J; Giles F J; O'Brien S
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Ferrajoli A; O'Brien S; Keating M J
Alemtuzumab: a novel monoclonal antibody.
Expert opinion on biological therapy 2001;1(6):1059-65.
2001: Cortes J; O'Brien S; Loscertales J; Kantarjian H; Giles F; Thomas D; Koller C; Keating M
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Cancer 2001;92(8):2016-22.
2001: Beran M; Shen Y; Kantarjian H; O'Brien S; Koller C A; Giles F J; Cortes J; Thomas D A; Faderl S; Despa S; Estey E H
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Aboul-Nasr R; O'Brien S; Freireich E J; Ginsberg C F; Kantarjian H M; Koller C A; Keating M J; Albitar M
"T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.
Leukemia & lymphoma 2001;42(5):1023-31.
2001: Talpaz M; O'Brien S; Rose E; Gupta S; Shan J; Cortes J; Giles F J; Faderl S; Kantarjian H M
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Cortes J; Estey E; O'Brien S; Giles F; Shen Y; Koller C; Beran M; Thomas D; Keating M; Kantarjian H
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Ibrahim S; Keating M; Do K A; O'Brien S; Huh Y O; Jilani I; Lerner S; Kantarjian H M; Albitar M
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.
Blood 2001;98(1):181-6.
2001: Giles F J; Shen Y; Kantarjian H M; Korbling M J; O'Brien S; Anderlini P; Donato M; Pierce S; Keating M J; Freireich E J; Estey E
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Ravandi F; Kantarjian H; Cohen A; Davis M; O'Brien S; Anderlini P; Andersson B; Claxton D; Donato M; Gajewski J; Khouri I; Korbling M; Ueno N; deVos D; Champlin R; Giralt S
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Bone marrow transplantation 2001;27(12):1221-5.
2001: Ravandi F; Kantarjian H M; Talpaz M; O'Brien S; Faderl S; Giles F J; Thomas D; Cortes J; Andreeff M; Estrov Z; Rios M B; Albitar M
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Ferrajoli A; Manshouri T; Estrov Z; Keating M J; O'Brien S; Lerner S; Beran M; Kantarjian H M; Freireich E J; Albitar M
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):795-9.
2001: Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez C O; Ramakrishna P; Rosner G L; Hodge J P; O'Brien S; Keating M J
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2142-52.
2001: Aguayo A; Manshouri T; O'Brien S; Keating M; Beran M; Koller C; Kantarjian H; Rogers A; Albitar M
Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL).
Leukemia research 2001;25(4):279-85.
2001: Giles F J; Cortes J E; Baker S D; Thomas D A; O'Brien S; Smith T L; Beran M; Bivins C; Jolivet J; Kantarjian H M
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2001: Fayad L; Keating M J; Reuben J M; O'Brien S; Lee B N; Lerner S; Kurzrock R
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
Blood 2001;97(1):256-63.
2001: Shimoni A; Gajewski J A; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(10):568-75.
2000: Keating M; O'Brien S
High-dose rituximab therapy in chronic lymphocytic leukemia.
Seminars in oncology 2000;27(6 Suppl 12):86-90.
2000: Ibrahim S; Estey E H; Pierce S; Glassman A; Keating M; O'Brien S; Kantarjian H M; Albitar M
11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
American journal of clinical pathology 2000;114(5):793-7.
2000: Faderl S; Kantarjian H M; Talpaz M; O'Brien S
New treatment approaches for chronic myelogenous leukemia.
Seminars in oncology 2000;27(5):578-86.
2000: Kantarjian H M; Giles F J; O'Brien S; Giralt S; Talpaz M
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Kantarjian H M; Talpaz M; Smith T L; Cortes J; Giles F J; Rios M B; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: Kozuch P; Talpaz M; Faderl S; O'Brien S; Freireich E J; Kantarjian H
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha: a synergistic correlation?
Cancer 2000;89(7):1482-9.
2000: Rodriguez J; Keating M J; O'Brien S; Champlin R E; Khouri I F
Allogeneic haematopoietic transplantation for Richter's syndrome.
British journal of haematology 2000;110(4):897-9.
2000: Aguayo A; Kantarjian H; Manshouri T; Gidel C; Estey E; Thomas D; Koller C; Estrov Z; O'Brien S; Keating M; Freireich E; Albitar M
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Blood 2000;96(6):2240-5.
2000: Aguayo A; O'Brien S; Keating M; Manshouri T; Gidel C; Barlogie B; Beran M; Koller C; Kantarjian H; Albitar M
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia.
Blood 2000;96(2):768-70.
2000: Ravandi-Kashani F; O'Brien S; Manshouri T; Lerner S; Sim S; Dodd K; Kantarjian H; Freireich E; Keating M; Albitar M
Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia.
Leukemia research 2000;24(6):469-74.
2000: Kornblau S M; Vu H T; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May W S
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1401-9.
2000: Keating M J; Smith T L; Lerner S; O'Brien S; Robertson L E; Kantarjian H; Freireich E J
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):71-85.
2000: Haidar M A; Kantarjian H; Manshouri T; Chang C Y; O'Brien S; Freireich E; Keating M; Albitar M
ATM gene deletion in patients with adult acute lymphoblastic leukemia.
Cancer 2000;88(5):1057-62.
2000: Cortes J; Estey E; Beran M; O'Brien S; Giles F; Koller C; Keating M; Kantarjian H
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: Kantarjian H M; O'Brien S; Smith T L; Cortes J; Giles F J; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha C S; Keating M J; Murphy S; Freireich E J
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: Kaban K; Kantarjian H; Talpaz M; O'Brien S; Cortes J; Giles F J; Pierce S; Albitar M
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith T L; Rios M B; Kantarjian H
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):147-52.
1999: Kantarjian H M; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios M B; Croce C M; Albitar M
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Partyka S; O'Brien S; Podoloff D; Kantarjian H; Keating M J
The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation.
Leukemia & lymphoma 1999;36(1-2):151-5.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Koller C A; Kantarjian H M; Feldman E J; O'Brien S; Rios M B; Estey E; Keating M
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Cancer 1999;86(11):2246-51.
1999: Lin C W; O'Brien S; Faber J; Manshouri T; Romaguera J; Huh Y O; Kantarjian H; Keating M; Albitar M
De novo CD5+ Burkitt lymphoma/leukemia.
American journal of clinical pathology 1999;112(6):828-35.
1999: Sacchi S; Kantarjian H M; Freireich E J; O'Brien S; Cortes J; Rios M B; Kornblau S; Giles F J; Koller C; Gajewski J; Talpaz M
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Thomas D A; Kantarjian H; Smith T L; Koller C; Cortes J; O'Brien S; Giles F J; Gajewski J; Pierce S; Keating M J
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Estey E H; Giles F J; Kantarjian H; O'Brien S; Cortes J; Freireich E J; Lopez-Berestein G; Keating M
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Beran M; Estey E; O'Brien S; Cortes J; Koller C A; Giles F J; Kornblau S; Andreeff M; Vey N; Pierce S R; Hayes K; Wong G C; Keating M; Kantarjian H
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Leukemia & lymphoma 1999;35(1-2):109-18.
1999: Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2491-7.
1999: Starostik P; O'Brien S; Chung C Y; Haidar M; Manshouri T; Kantarjian H; Freireich E; Keating M; Albitar M
The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia.
Leukemia research 1999;23(9):795-801.
1999: Thomas D A; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister F B; Cabanillas F F; Murphy S; Keating M J; Kantarjian H
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2461-70.
1999: Seong D; Kantarjian H M; Albitar M; Arlinghaus R; Xu J; Talpaz M; Rios M B; Guo J Q; O'Brien S; Siciliano M
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):955-9.
1999: Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian H M
The biology of chronic myeloid leukemia.
The New England journal of medicine 1999;341(3):164-72.
1999: O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios M B; Talpaz M
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
Blood 1999;93(12):4149-53.
1999: Dabaja B S; Faderl S; Thomas D; Cortes J; O'Brien S; Nasr F; Pierce S; Hayes K; Glassman A; Keating M; Kantarjian H M
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(6):869-72.
1999: Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):577-83.
1999: Cortes J E; Kantarjian H M; O'Brien S; Giles F; Keating M J; Freireich E J; Estey E H
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Weiser M A; O'Brien S; Escalante C; Manzullo E
Tuberculosis meningitis in a patient with acute myelogenous leukemia.
Leukemia & lymphoma 1999;33(1-2):187-92.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Investigational new drugs 1999;17(1):89-95.
1999: Cortes J; O'Brien S; Estey E; Giles F; Keating M; Kantarjian H
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1998: Jeha S; Kantarjian H; O'Brien S; Vitek L; Beran M
Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia.
Leukemia & lymphoma 1998;32(1-2):159-64.
1998: Rodriguez J; Cortes J; Smith T; O'Brien S; Rios M B; Talpaz M; Kantarjian H
Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3782-7.
1998: Starostik P; Manshouri T; O'Brien S; Freireich E; Kantarjian H; Haidar M; Lerner S; Keating M; Albitar M
Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.
Cancer research 1998;58(20):4552-7.
1998: Cortes J; Talpaz M; O'Brien S; Rios M B; Majlis A; Keating M; Freireich E J; Kantarjian H
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3279-85.
1998: Anaissie E J; Kontoyiannis D P; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating M J
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Annals of internal medicine 1998;129(7):559-66.
1998: Jendiroba D B; Lichtiger B; Anaissie E; Reddy V; O'Brien S; Kantarjian H; Freireich E J
Evaluation and comparison of three mobilization methods for the collection of granulocytes.
Transfusion 1998;38(8):722-8.
1998: Khouri I F; Keating M; Körbling M; Przepiorka D; Anderlini P; O'Brien S; Giralt S; Ippoliti C; von Wolff B; Gajewski J; Donato M; Claxton D; Ueno N; Andersson B; Gee A; Champlin R
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2817-24.
1998: Keating M J; O'Brien S; Lerner S; Koller C; Beran M; Robertson L E; Freireich E J; Estey E; Kantarjian H
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood 1998;92(4):1165-71.
1998: O'Brien S
Clinical challenges in chronic lymphocytic leukemia.
Seminars in hematology 1998;35(3 Suppl 3):22-6.
1998: Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus R B; Lydon N B; Kantarjian H
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1661-72.
1998: Gandhi V; Plunkett W; Kantarjian H; Talpaz M; Robertson L E; O'Brien S
Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2321-31.
1998: Cortes J; Kantarjian H; O'Brien S; Kurzrock R; Keating M; Talpaz M
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(6):860-4.
1998: Cortes J; Fayad L; Kantarjian H; O'Brien S; Lee M S; Talpaz M
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1998;12(4):455-62.
1998: DeLima M; Albitar M; O'Brien S; Pierce S; Kantarjian H; Andreeff M; Fayad L; Keating M; Estey E
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
The American journal of medicine 1998;104(3):246-51.
1998: Sacchi S; Kantarjian H M; Smith T L; O'Brien S; Pierce S; Kornblau S; Beran M; Keating M J; Talpaz M
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):882-9.
1998: de Lima M; O'Brien S; Lerner S; Keating M J
Chronic lymphocytic leukemia in the young patient.
Seminars in oncology 1998;25(1):107-16.
1998: Kornblau S M; Kantarjian H; O'Brien S; Andreeff M; Koller C A; Beran M; Keating M; Estey E
CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
Leukemia & lymphoma 1998;28(3-4):371-5.
1998: Munker R; Kantarjian H; O'Brien S; Keating M; Andreeff M; Estey E H
Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule.
Acta haematologica 1998;99(2):106-8.
1997: Kantarjian H M; Talpaz M; O'Brien S; Kurzrock R; Gutterman J; Keating M J; McCredie K B; Freireich E J
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo M G; Rios M B; Keating M; Kantarjian H
Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2377-84.
1997: Koller C A; Kantarjian H M; Thomas D; O'Brien S; Rios M B; Kornblau S; Murphy S; Keating M
The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(12):2039-44.
1997: de Lima M; Strom S S; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E; Estey E
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
Blood 1997;90(12):4719-24.
1997: O'Brien S; Kantarjian H; Beran M; Koller C; Talpaz M; Lerner S; Keating M J
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1631-5.
1997: Dignani M C; Anaissie E J; Hester J P; O'Brien S; Vartivarian S E; Rex J H; Kantarjian H; Jendiroba D B; Lichtiger B; Andersson B S; Freireich E J
Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1621-30.
1997: Sacchi S; Kantarjian H M; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating M J; Talpaz M
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1610-6.
1997: Rodriguez-Monge E J; Cortes J E; O'Brien S; Talpaz M; Kantarjian H M
Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia.
Cancer 1997;80(3):396-400.
1997: Cortes J; Kantarjian H; O'Brien S; Beran M; Estey E; Keating M; Talpaz M
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(7):929-32.
1997: Talpaz M; Kantarjian H M; O'Brien S; Kurzrock R
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):291-305.
1997: O'Brien S; Thall P F; Siciliano M J
Cytogenetics of chronic myelogenous leukaemia.
Baillière's clinical haematology 1997;10(2):259-76.
1997: Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Blood 1997;89(12):4531-6.
1997: Cortes J; Kantarjian H; Talpaz M; O'Brien S; Beran M; Koller C; Keating M
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(6):788-91.
1997: Fayad L; Kantarjian H; O'Brien S; Seong D; Albitar M; Keating M; Talpaz M
Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(5):767-71.
1997: Kurzrock R; Strom S S; Estey E; O'Brien S; Keating M J; Jiang H; Adams T; Talpaz M
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1803-10.
1997: Khouri I F; Przepiorka D; van Besien K; O'Brien S; Palmer J L; Lerner S; Mehra R C; Vriesendorp H M; Andersson B S; Giralt S; Körbling M; Keating M J; Champlin R E
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
British journal of haematology 1997;97(2):466-73.
1997: Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
Studies of decitabine with allogeneic progenitor cell transplantation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 1():S32-4.
1996: Keating M J; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: Fayad L; Robertson L E; O'Brien S; Manning J T; Wright S; Hagemeister F; Cabanillas F; Keating M J
Hodgkin's disease variant of Richter's syndrome: experience at a single institution.
Leukemia & lymphoma 1996;23(3-4):333-7.
1996: O'Brien S; Kantarjian H; Talpaz M
Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha.
Leukemia & lymphoma 1996;23(3-4):247-52.
1996: Kornblau S M; Gandhi V; Andreeff H M; Beran M; Kantarjian H M; Koller C A; O'Brien S; Plunkett W; Estey E
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(10):1563-9.
1996: Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese J L; Andreeff M; Keating M; Estey E
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 1996;88(7):2473-9.
1996: Anderlini P; Ghaddar H M; Smith T L; Pierce S; Kantarjian H M; O'Brien S; Keating M J; Freireich E J; Estey E H
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):964-9.
1996: Anderlini P; Luna M; Kantarjian H M; O'Brien S; Pierce S; Keating M J; Estey E H
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):600-8.
1996: Cortes J; Kantarjian H; O'Brien S; Robertson L E; Pierce S; Talpaz M
Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
The American journal of medicine 1996;100(4):452-5.
1996: Kantarjian H M; O'Brien S; Anderlini P; Talpaz M
Treatment of myelogenous leukemia: current status and investigational options.
Blood 1996;87(8):3069-81.
1996: Sarris A; Cortes J; Kantarjian H; Pierce S; Smith T; Keating M; Koller C; Kornblau S; O'Brien S; Andreeff M
Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.
Leukemia & lymphoma 1996;21(1-2):85-92.
1996: Kantarjian H M; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang L Y; Rios M B; Keating M J; Meyer M
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):396-401.
1996: O'Brien S; Jeha S; Kantarjian H; Pisa P; Jin G; Keating M; Beran M
Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(2):338-44.
1996: Pollicardo N; O'Brien S; Estey E H; al-Bitar M; Pierce S; Keating M; Kantarjian H M
Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(1):27-31.
1996: Majlis A; Smith T L; Talpaz M; O'Brien S; Rios M B; Kantarjian H M
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):196-203.
1996: O'Brien S; Kantarjian H; Keating M J
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 6():S27-33.
1995: Jeha S; Kantarjian H; O'Brien S; Huh Y; Pisa P; Ordonez N; Beran M
Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency.
Blood 1995;86(11):4278-85.
1995: Anderlini P; Benjamin R S; Wong F C; Kantarjian H M; Andreeff M; Kornblau S M; O'Brien S; Mackay B; Ewer M S; Pierce S A
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2827-34.
1995: O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson L E; Hester J; Rios M B; Andreeff M; Talpaz M
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
Blood 1995;86(9):3322-6.
1995: Verschraegen C F; Kantarjian H M; Hirsch-Ginsberg C; Lee M S; O'Brien S; Rios M B; Stass S A; Keating M; Talpaz M
The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations.
Cancer 1995;76(6):992-7.
1995: Sacchi S; Kantarjian H; O'Brien S; Cohen P R; Pierce S; Talpaz M
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2401-7.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating M J
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1444-9.
1995: Seymour J F; Robertson L E; O'Brien S; Lerner S; Keating M J
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Leukemia & lymphoma 1995;18(5-6):493-6.
1995: O'Brien S; Kantarjian H; Beran M; Robertson L E; Koller C; Lerner S; Keating M J
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Blood 1995;86(4):1298-300.
1995: Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan K W; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
Cytokines and molecular therapy 1995;1(2):115-22.
1995: Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich E J; Estey E
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):965-71.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating M J
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):943-5.
1995: Spiekermann K; O'Brien S; Estey E
Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain.
Cancer 1995;75(7):1594-7.
1995: Estey E H; Kantarjian H M; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Cytokines and molecular therapy 1995;1(1):21-8.
1995: O'Brien S; Kantarjian H; Ellis A; Zwelling L; Estey E; Keating M
Topotecan in chronic lymphocytic leukemia.
Cancer 1995;75(5):1104-8.
1995: Kantarjian H M; Smith T L; O'Brien S; Beran M; Pierce S; Talpaz M
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Annals of internal medicine 1995;122(4):254-61.
1995: Cortes J E; Kantarjian H; O'Brien S; Keating M; Pierce S; Freireich E J; Estey E
Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(1):115-7.
1995: O'Brien S; del Giglio A; Keating M
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Blood 1995;85(2):307-18.
1995: Hester J P; Dignani M C; Anaissie E J; Kantarjian H M; O'Brien S; Freireich E J
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection.
Journal of clinical apheresis 1995;10(4):188-93.
1994: Dimopoulos M A; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R
Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(12):2694-8.
1994: Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich E J; Keating M; Pierce S; Estey E
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2174-8.
1994: Robertson L E; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating M J
Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2047-51.
1994: Wright S J; Robertson L E; O'Brien S; Plunkett W; Keating M J
The role of fludarabine in hematological malignancies.
Blood reviews 1994;8(3):125-34.
1994: Kantarjian H M; O'Brien S; Smith T; Estey E H; Beran M; Preti A; Pierce S; Keating M J
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: O'Brien S; Kurzrock R; Duvic M; Kantarjian H; Stass S; Robertson L E; Estey E; Pierce S; Keating M J
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Blood 1994;84(3):733-8.
1994: Giralt S; O'Brien S; Weeks E; Luna M; Kantarjian H
Leukemia cutis in acute promyelocytic leukemia: report of three cases after treatment with all-trans retinoic acid.
Leukemia & lymphoma 1994;14(5-6):453-6.
1994: Preti H A; O'Brien S; Giralt S; Beran M; Pierce S; Kantarjian H M
Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients.
The American journal of medicine 1994;97(1):60-5.
1994: Cortes J E; Kantarjian H; O'Brien S; Robertson L E; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
Cancer 1994;73(12):2946-52.
1994: Bodey G P; Anaissie E J; Elting L S; Estey E; O'Brien S; Kantarjian H
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.
Cancer 1994;73(8):2099-106.
1994: Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson L E; Koller C; Kornblau S
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):671-8.
1994: O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
The New England journal of medicine 1994;330(5):319-22.
1994: Kornblau S M; Chen N; del Giglio A; O'Brien S; Deisseroth A B
Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia.
Cancer research 1994;54(1):242-6.
1994: Keating M J; O'Brien S; Plunkett W; Robertson L E; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1994: Keating M J; McLaughlin P; Plunkett W; Robertson L E; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():79-83.
1994: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Li Y Y; Gandhi V
The expanding role of fludarabine in hematologic malignancies.
Leukemia & lymphoma 1994;14 Suppl 2():11-6.
1994: Keating M J; Estey E; O'Brien S; Kantarjian H; Robertson L E; Plunkett W
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1993: Anaissie E J; Kontoyiannis D P; Vartivarian S; Kantarjian H M; O'Brien S; Giralt S A; Andersson B S; Karl C; Champlin R E; Bodey G P
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(6):1022-31.
1993: Kantarjian H M; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating M J
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Cancer 1993;72(10):2950-5.
1993: Robertson L E; Pugh W; O'Brien S; Kantarjian H; Hirsch-Ginsberg C; Cork A; McLaughlin P; Cabanillas F; Keating M J
Richter's syndrome: a report on 39 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1985-9.
1993: Suki S; Kantarjian H; Gandhi V; Estey E; O'Brien S; Beran M; Rios M B; Plunkett W; Keating M
Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
Cancer 1993;72(7):2155-60.
1993: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang L Y; Gandhi V
New initiatives with fludarabine monophosphate in hematologic malignancies.
Seminars in oncology 1993;20(5 Suppl 7):13-20.
1993: O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson L E; Lerner S; Keating M
Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
Blood 1993;82(6):1695-700.
1993: Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich E J; Andersson B S; O'Brien S; Andreeff M; Fisher H; Cork A
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
The New England journal of medicine 1993;329(11):757-61.
1993: Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson B S; Kohli V; Kantarjian H
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Cancer research 1993;53(15):3603-10.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating M J
Fludarabine therapy in Waldenström's macroglobulinemia.
The American journal of medicine 1993;95(1):49-52.
1993: Del Giglio A; O'Brien S; Ford R J; Manning J; Saya H; Keating M; Johnston D; Chamone D F; Deisseroth A B
Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL).
Leukemia & lymphoma 1993;10(4-5):265-71.
1993: Keating M J; O'Brien S; Kantarjian H; Plunkett W; Estey E; Koller C; Beran M; Freireich E J
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: Kemena A; O'Brien S; Kantarjian H; Robertson L; Koller C; Beran M; Estey E; Plunkett W; Lerner S; Keating M J
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Kantarjian H M; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios M B; Plunkett W; Keating M J
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: Dimopoulos M A; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating M J; Freireich E J; Alexanian R
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Derderian P M; Kantarjian H M; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
The American journal of medicine 1993;94(1):69-74.
1993: Keating M J; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Chronic lymphocytic leukemia--correlation of response and survival.
Leukemia & lymphoma 1993;11 Suppl 2():167-75.
1993: Keating M J; O'Brien S; Kantarjian H; Robertson L B; Koller C; Beran M; Estey E
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;10 Suppl():139-45.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Estey E E; Keating M J; Alexanian R
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Leukemia & lymphoma 1993;11 Suppl 2():105-8.
1993: Estey E; Pierce S; Kantarjian H; O'Brien S; Beran M; Andreeff M; Escudier S; Koller C; Kornblau S; Robertson L
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Leukemia & lymphoma 1993;11 Suppl 2():59-63.
1992: O'Brien S; Kantarjian H; Freireich E; Johnston D; Nguyen K; Beran M
CI-973, a new platinum derivative with potential antileukemic activity.
Cancer research 1992;52(15):4130-4.
1992: Estey E; Thall P F; Kantarjian H; O'Brien S; Koller C A; Beran M; Gutterman J; Deisseroth A; Keating M
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.
Blood 1992;79(9):2246-55.
1992: Kantarjian H M; Keating M J; Estey E H; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: del Giglio A; O'Brien S; Ford R; Saya H; Manning J; Keating M; Johnston D; Khetan R; el-Naggar A; Deisseroth A
Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia.
Blood 1992;79(10):2717-20.
1992: Kantarjian H M; Talpaz M; Kontoyiannis D; Gutterman J; Keating M J; Estey E H; O'Brien S; Rios M B; Beran M; Deisseroth A
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):398-405.
1992: Kantarjian H M; Estey E H; O'Brien S; Anaissie E; Beran M; Rios M B; Keating M J; Gutterman J
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Estey E; Trujillo J M; Cork A; O'Brien S; Beran M; Kantarjian H; Keating M; Freireich E J; Stass S
AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
Hematologic pathology 1992;6(1):43-8.
1992: Keating M J; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich E J
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():78-80.
1991: Kurzrock R; Talpaz M; Estey E; O'Brien S; Estrov Z; Gutterman J U
Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(11):985-90.
1991: Kantarjian H M; Talpaz M; Keating M J; Estey E H; O'Brien S; Beran M; McCredie K B; Gutterman J; Freireich E J
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: O'Brien S; Kantarjian H; Estey E; Koller C; Beran M; McCredie K; Keating M
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
Cancer 1991;68(4):691-4.
1991: Kurzrock R; Talpaz M; Gomez J A; Estey E H; O'Brien S; Hirsch-Ginsberg C; Koller C; Freireich E J; Gutterman J U
Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients.
British journal of haematology 1991;78(3):352-8.
1991: O'Brien S; Witt R; Talpaz M; Kantarjian H
Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
Cancer 1991;67(7):1946-9.
1991: Estey E H; Kurzrock R; Talpaz M; McCredie K B; O'Brien S; Kantarjian H M; Keating M J; Deisseroth A B; Gutterman J U
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: Kantarjian H M; Childs C; O'Brien S; Huh Y; Beran M; Schachner J; Koller C; Keating M J
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
The American journal of medicine 1991;90(2):223-8.
1991: O'Brien S; Benvenuto J A; Estey E; Beran M; Felder T B; Keating M
Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
Cancer research 1991;51(3):935-8.
1991: Keating M J; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs C C; Freireich E J; McCredie K B
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):44-9.
1990: Kantarjian H M; Walters R S; Keating M J; Smith T L; O'Brien S; Estey E H; Huh Y O; Spinolo J; Dicke K; Barlogie B
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Kantarjian H M; Walters R L; Keating M J; Estey E H; O'Brien S; Schachner J; McCredie K B; Freireich E J
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1989: O'Brien S; Kantarjian H M; Keating M; Gagnon G; Cork A; Trujillo J; McCredie K B
Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1081-6.
1989: Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman J U
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
The American journal of medicine 1989;86(5):554-8.
1988: O'Brien S; Kantarjian H; Shtalrid M; Blick M; Beran M; Talpaz M
Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Hematologic pathology 1988;2(1):25-9.
1987: O'Brien S; Kantarjian H M; Talpaz M; Cork A; Trujillo J; Beran M
The effect of long-term marrow culture on the nonadherent Philadelphia chromosome-positive clone in chronic myelogenous leukemia: preliminary observations.
Hematologic pathology 1987;1(3):167-72.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Susan O'Brien

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Susan O'Brien (preview)

All Publications